Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse til at undersøge brugen af ​​VH3810109 med eller uden Fostemsavir (FTR) for at reducere størrelsen og aktiviteten af ​​det virale reservoir hos mennesker, der lever med HIV (ENTRANCE)

25. september 2026 opdateret af: ViiV Healthcare

En sonderende fase 1b, multicenter, randomiseret, åben-label-undersøgelse for at undersøge virkningen af ​​administrationen af ​​intravenøs VH3810109 med eller uden oral fostemsavir i kombination med integraseinhibitorbaseret antiretroviral terapi på det virale reservoir i voksne, der lever med HIV-1

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

107

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Brussels, Belgien, 1000
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgien, 9000
        • GSK Investigational Site
    • Capital Region
      • Hvidovre, Capital Region, Danmark, 2650
        • GSK Investigational Site
    • Central Jutland
      • Aarhus N, Central Jutland, Danmark, 8200
        • GSK Investigational Site
      • London, Det Forenede Kongerige, SE1 7EH
        • GSK Investigational Site
      • London, Det Forenede Kongerige, NW3 2QG
        • GSK Investigational Site
      • London, Det Forenede Kongerige, W2 1NY
        • GSK Investigational Site
    • California
      • Bakersfield, California, Forenede Stater, 93309
        • GSK Investigational Site
      • San Diego, California, Forenede Stater, 92103
        • GSK Investigational Site
    • Florida
      • Ft. Pierce, Florida, Forenede Stater, 34982-7148
        • GSK Investigational Site
      • Orlando, Florida, Forenede Stater, 32803-1851
        • GSK Investigational Site
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • GSK Investigational Site
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64111
        • GSK Investigational Site
      • St Louis, Missouri, Forenede Stater, 63110
        • GSK Investigational Site
    • New York
      • New York, New York, Forenede Stater, 10032
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45267
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • GSK Investigational Site
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • GSK Investigational Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75246-2004
        • GSK Investigational Site
      • Dallas, Texas, Forenede Stater, 75208-4599
        • GSK Investigational Site
      • Rotterdam, Holland, 3015 GD
        • GSK Investigational Site
      • Barcelona, Spanien, 08036
        • GSK Investigational Site
      • Barcelona, Spanien, 08035
        • GSK Investigational Site
      • Barcelona, Spanien, 08003
        • GSK Investigational Site
      • Barcelona, Spanien, 8907
        • GSK Investigational Site
      • Barcelona, Spanien, 08026
        • GSK Investigational Site
      • Barcelona, Spanien, 08916
        • GSK Investigational Site
      • Córdoba, Spanien, 14004
        • GSK Investigational Site
      • La Laguna Santa Cruz, Spanien, 38320
        • GSK Investigational Site
      • Madrid, Spanien, 28041
        • GSK Investigational Site
      • Madrid, Spanien, 28040
        • GSK Investigational Site
      • Madrid, Spanien, 28046
        • GSK Investigational Site
      • Madrid, Spanien, 28034
        • GSK Investigational Site
      • Madrid, Spanien, 28031
        • GSK Investigational Site
      • Madrid, Spanien, 28020
        • GSK Investigational Site
      • Palma de Mallorca, Spanien, 07120
        • GSK Investigational Site
      • Palma de Mallorca, Spanien, 7198
        • GSK Investigational Site
      • Seville, Spanien, 41013
        • GSK Investigational Site
      • Valencia, Spanien, 46026
        • GSK Investigational Site
      • Valencia, Spanien, 46014
        • GSK Investigational Site
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spanien, 28224
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

AGE

• Age between 18 years and 70 years old at the time of obtaining informed consent.

SEX AND GENDER • Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.

PARTICIPANT KEY CHARACTERISTICS • Participant has a documented diagnosis of HIV-1 infection. Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.

Population 1 only:

  • Plasma HIV-1 RNA >=2000 copies/milliliter (c/mL) at Screening.
  • CD4+ T cell count >=300 cells/microliter (μL) at Screening.
  • Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.

Population 2 only:

  • Participant is stably virologically suppressed (plasma HIV-1 RNA <50 c/mL).
  • Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
  • CD4+ T cell count >=450 cells/μL at Screening.

WEIGHT

• Body weight >=50 kg to <=115 kg.

INFORMED CONSENT • Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.

Exclusion Criteria:

CONCURRENT MEDICAL CONDITIONS & MEDICAL HISTORY

  • Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
  • Participant has documented diagnosis of HIV-2 infection.
  • Participant is known to have acquired HIV via perinatal transmission.
  • Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
  • Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
  • Ongoing or clinically relevant pancreatitis.
  • Current HIV-related kidney disease.
  • History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.

CARDIAC & CARDIOVASCULAR CONDITIONS

  • Participants who are at clinically significant risk of cardiovascular disease.
  • Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
  • Confirmed QTcF value outside normal range at Screening or Day 1.

HEPATIC CONDITIONS

  • History of clinically relevant hepatitis in the 6 months prior to Screening.
  • Participants with severe hepatic impairment.
  • Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
  • Unstable liver disease.
  • History of liver cirrhosis with or without hepatitis viral co-infection.

NEUROPSYCHIATRIC CONDITIONS • Participants who pose a significant suicide risk.

LABORATORY DIAGNOSTIC ASSESSMENTS

  • Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
  • Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
  • Alanine transferase (ALT) >=3 times the upper limit of normal (ULN) at Screening.
  • Estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m^2.
  • Hemoglobin >=Grade 2 at Screening.
  • Platelets >=Grade 2 at Screening.
  • Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
  • Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.

Population 2 only:

• Two or more plasma HIV-1 RNA results >=50 c/mL in the 18 months prior to Screening.

INFECTIOUS DISEASES

  • Active hepatitis B virus (HBV) co-infection.
  • Active hepatitis C virus (HCV) co-infection.
  • Participant has untreated syphilis before enrolment.
  • Known history of active Mycobacterium TB disease (regardless of treatment status).

ANTIRETROVIRAL RESISTANCE • Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.

PRIOR AND CONCOMITANT MEDICATIONS

  • Prior use of any of the following agents:

    - long-acting ARVs (any dose in the past 24 months or within 5 half-lives [whichever is longer])

    - FTR (any lifetime use)

    - HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)

    - HIV-1 monoclonal antibody therapy (any lifetime use).

  • Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.

  • History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.

  • Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.

  • Treatment with any of the following agents within 30 days of enrolment:

    - radiation therapy

    • cytotoxic chemotherapeutic agents
    • anti-tuberculosis therapy
    • immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
  • Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.

Population 1 only:

• Known use of PrEP or PEP within <30 days (for oral agents) or <52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result >=30 days after the last dose of oral PrEP or PEP (or >=52 weeks after the last dose of LA PrEP) are not excluded.

Population 2 only:

• Current use of NNRTI-containing ART.

OTHER EXCLUSIONS

  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
  • Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
  • Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participant is currently participating in, or anticipates being selected for, any other interventional study.
  • Participant is known or suspected to be an HIV long-term non-progressor or elite controller, based on historical off-treatment plasma HIV-1 RNA results.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Participants receiving SOC INSTI-based ART in Randomized Intervention Phase (Step 1)

A SOC INSTI-based ART regimen will be administered.

Eksperimentel: Participants receiving SOC INSTI-based ART+VH3810109 in Randomized Intervention Phase (Step 1)

A SOC INSTI-based ART regimen will be administered.

VH3810109 will be administered.

Andre navne:
  • Lotivibart (LVB)
Eksperimentel: Participants receiving SOC INSTI-based ART+VH3810109+FTR in Randomized Intervention Phase (Step 1)

A SOC INSTI-based ART regimen will be administered.

VH3810109 will be administered.

Andre navne:
  • Lotivibart (LVB)

Fostemsavir will be administered.

Andre navne:
  • Rukobia
Eksperimentel: Participants receiving VH3810109 in ATI Phase (Step 2)

VH3810109 will be administered.

Andre navne:
  • Lotivibart (LVB)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cells
Tidsramme: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12

Sekundære resultatmål

Resultatmål
Tidsramme
Randomized Intervention Phase (Step 1): Change from baseline in total, intact, and defective proviral HIV-1 DNA per million CD4+ T cells
Tidsramme: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Absolute change in cell-associated HIV-1 RNA/proviral DNA ratios in CD4+ T cells
Tidsramme: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Absolute values for HIV-1-specific CD8+ T cell count
Tidsramme: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Change from baseline in HIV-1-specific CD8+ T cell count
Tidsramme: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Number of participants with Grade 3 and Grade 4 adverse events (AEs)
Tidsramme: From Baseline (Day 1) to Month 15
From Baseline (Day 1) to Month 15
Randomized Intervention Phase (Step 1): Number of participants with serious adverse events (SAEs), deaths and AEs leading to discontinuation of study intervention
Tidsramme: From Baseline (Day 1) to Month 15
From Baseline (Day 1) to Month 15
ATI Phase (Step 2): Time to ART restart
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
ATI Phase (Step 2): Number of participants with Grade 3 and Grade 4 AEs
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
ATI Phase (Step 2): Number of participants with SAEs and deaths
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
ATI Phase (Step 2): Number of participants with disease progression (HIV-associated conditions, acquired immunodeficiency syndrome [AIDS] and death)
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. juli 2025

Primær færdiggørelse (Anslået)

22. januar 2027

Studieafslutning (Anslået)

6. september 2028

Datoer for studieregistrering

Først indsendt

26. juni 2025

Først indsendt, der opfyldte QC-kriterier

26. juni 2025

Først opslået (Faktiske)

8. juli 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 221794
  • 2025-520629-19-00 (Anden identifikator: EU CT Number)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD-delingsadgangskriterier

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .